Clinical Research on Advanced Primary Liver Cancer under Systemic Treatment of TACE Combined with EOF Regimen

Jinyou YU,Zhengfeng ZHU,Jianling QIU,Jianjun ZHU

DOI: https://doi.org/10.3969/j.issn.1674-0742.2014.34.010

2014-01-01

Abstract:Objective To evaluate the treatment efficacy and toxicity of advanced primary liver cancer under the systemic treat_ment of TACE combined with EOF regimen. Methods Transcatheter arterial chemoembolization was given to 32 cases in group A (control group). Systemic venous chemotherapy with EOF regimen was given to 26 cases in group B(treatment group) after they un_derwent transcatheter arterial chemoembolization for 2 times until the disease progressed or the patients were not appropriate to continue the treatment or the toxicity was intolerable. 4-6 weeks after transcatheter arterial chemoembolization, group B began to undergo chemotherapy with EOF regimen, namely, the detailed regimen is pirarubicin 40 mg/m2 d1, oxaliplatin (OXA) 85 mg/m2 d1-8, 5-FU 0.5 g/m2 d1-5. The evaluation of treatment efficacy should be given after 2 continuous circles based on 28 days per circle. Results The overall response rate (RR) in group A is lower than that in group B (37.5% VS 61.5%), disease control rate (DCR) is lower than that in group B(84.39%VS 96.1%), 1-year survival rate is lower than that in group B(50%VS 88.4%), 2-year survival rate is lower than that in group B (18.7%VS 61.5%), 3-year survival rate is lower than that in group B (12.5%VS 19%). The primary toxic side effect is bone marrow suppression, IV° adverse reactions are seldom reflected. Conclusion For advanced primary liver cancer, systemic treatment of TACE combined with EOF regimen can obviously improve the efficacy and 1-year and 2-year survival rate with tolerable side effects and high compliance. It could be an effective treatment pattern for advanced prima_ry liver cancer.